null

null

null

null

null

null

null

null

null

Minimal debt; cash-funded clinical-stage biotech with ~$200M+ cash runway; 20% rate rise has negligible direct debt service impact

Low direct sensitivity; higher rates increase opportunity cost of cash holdings and raise discount rates, compressing pipeline NPV by ~15-20%

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

AAV vector manufacturing (single CDMOs) and oligonucleotide synthesis reagents sourced from limited US/European suppliers; geopolitical risk modest

Essentially no international revenue; pre-commercial stage; currency devaluation exposure is negligible and not applicable operationally

US-only operations and trials; no material international revenue markets; sovereign currency devaluation exposure effectively zero

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single CDMO partners for AAV gene therapy manufacturing; substitution would require 12-24 months regulatory revalidation

Clinical-stage biopharmaceutical; cloud disruption would impair R&D data systems but not patient trials; recovery within weeks using alternative platforms

No secondary revenue model; entirely grant/equity-funded R&D with no commercial product; cloud termination is operational inconvenience only

Moderate API coupling to bioinformatics platforms; gene therapy data pipelines are specialized but migratable within 1-3 months with significant cost

Not applicable; revenue model is drug development, not investment contracts; Howey Test risk index is negligible

Very High

Limited GDPR/CCPA exposure; patient trial data governed by HIPAA/FDA regulations; no consumer data monetization; compliance risk low-to-moderate

Minimal antitrust risk; no market dominance in any commercial segment; pre-revenue clinical-stage company with no pricing power to scrutinize

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0% recurring commercial revenue; 100% transactional/milestone-based (grants, collaborations); entirely pre-commercial with no subscription revenue

Future monetization via drug approvals, royalties, and potential licensing deals; current revenue from collaboration milestones only

No commercial pricing yet; future cardiac gene therapy pricing likely $500K-$3M per patient treatment, consistent with gene therapy market benchmarks

Potential high pricing power post-approval for rare cardiac diseases with limited alternatives; constrained by payer negotiation and CMS pressure

Post-commercialization gross margins expected 70-85% if manufacturing scales; near-term COGS dominated by CDMO batch costs

No free-rider risk; gene therapy is a one-time treatment model with no subscription churn; patient retention not applicable post-administration

Headcount-sublinear potential at scale; R&D-heavy now, but commercial launch requires sales force build; doubling revenue post-launch needs ~30-40% headcount growth

Marginal cost of growth is high pre-approval (clinical trial costs); post-approval, each additional patient treated has declining incremental manufacturing cost

Not applicable; no franchise network; company operates as integrated biotech without franchisee relationships

At 10x scale, CAC analogous to physician detailing and hospital formulary adoption; estimated $50K-$150K per prescribing cardiologist relationship

No meaningful network effects; gene therapy adoption is physician/hospital driven; patient base for rare cardiac indications is inherently small and finite

-61.7% Return on Assets (Negative equity)

Moderate-high resilience; heart failure is life-threatening and non-deferrable; but payer budget pressure in recessions could delay formulary approval

Future primary customers are hospital systems and academic cardiac centers treating advanced heart failure and genetic cardiomyopathies

Secondary customers include rare disease specialty pharmacies, cardiomyopathy specialist clinics, and potentially pediatric cardiac programs

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital reallocating toward IND-enabling and Phase 2 trial infrastructure; no legacy operations; all capex is future-state pipeline investment

0001858848

TNYA